CD40L - A Multipotent Molecule for Tumor Therapy

Publisher： Bentham Science Publishers

E-ISSN： 2212-3873|7|1|23-28

ISSN： 1871-5303

Source： Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.7, Iss.1, 2007-03, pp. : 23-28

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of the CD40-CD40L Dyad in Alzheimer's Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 9, Iss. 2, 2010-04 ,pp. : 149-155

Bentham Science Publishers

Access to resources Recommend Favorite

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

By English Diana P.   Bellone Stefania   Schwab Carlton L.   Roque Dana M.   Lopez Salvatore   Bortolomai Ileana   Cocco Emiliano   Bonazzoli Elena   Chatterjee Sudeshna   Ratner Elena   Silasi Dan-Arin   Azodi Masoud   Schwartz Peter E.   Rutherford Thomas J.   Santin Alessandro D.  

Cancer, Vol. 121, Iss. 3, 2015-02 ,pp. : 403-412

Blackwell Publishing

Access to resources Recommend Favorite

Small Molecule Toxins Targeting Tumor Receptors

By  

Current Pharmaceutical Design, Vol. 10, Iss. 19, 2004-07 ,pp. : 2311-2334

Bentham Science Publishers

Access to resources Recommend Favorite

Saponins in Tumor Therapy

By  

Mini Reviews in Medicinal Chemistry, Vol. 8, Iss. 6, 2008-06 ,pp. : 575-584

Bentham Science Publishers

Access to resources Recommend Favorite

Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?

By  

Current Cancer Drug Targets, Vol. 5, Iss. 6, 2005-09 ,pp. : 381-392

Bentham Science Publishers

Access to resources Recommend Favorite